Drug intelligence / Profile preview

Hebermin

Development stage
Unknown
Lead developer
Center for Genetic Engineering and Biotechnology
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Hebermin is a topical cream developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba. It is a combination product containing recombinant human epidermal growth factor (rhEGF), also known as nepidermin, and silver sulfadiazine. The rhEGF component acts as an agonist at the epidermal growth factor receptor (EGFR), stimulating the proliferation and migration of keratinocytes and fibroblasts to accelerate wound closure and tissue regeneration. Silver sulfadiazine provides broad-spectrum antimicrobial activity, preventing and treating infections at the wound site. Hebermin is primarily indicated for the treatment of partial and full-thickness burns, as well as chronic wounds such as diabetic foot ulcers and pressure sores. It is approved for use in Cuba and several other countries in Latin America and elsewhere.

Brand names
Hebermin
Other names
rhEGF + silver sulfadiazine creamrecombinant human epidermal growth factor cream
02

Targets

NeuraminidaseDHPS (Dihydropteroate synthase)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on Hebermin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hebermin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call